By employing clinically relevant primate models, RxGen enables accurate identification and characterization of toxicity, improve speeds candidate selection, decreases compound attrition, and improves time to market of small molecule therapeutics, biologics, and medical devices.

Toxicity endpoints

• Ocular
• CNS
• Systemic
• Clinical pathology
• Histopathology
• Imaging
• Study-specific endpoints

Design and execution

• Acute, subchronic, chronic
• Oral, intravenous, intramuscular, subcutaneous, intraperitoneal, ocular
• Reproductive
• Safety pharmacology study design to define endpoints for incorporation into larger follow-on toxicology, kinetic and clinical studies